MID in oncology also enhances treatment adherence and improves patient outcomes, according to Kenneth Komorny, PharmD, BCPS.

In this episode titled, Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical ...

As stroke systems of care evolve, clinicians are increasingly torn between the known safety of traditional, aggressive ...

In this clip, Katherine Tobon, PharmD, BCOP, of Moffitt Cancer Center, defines medically integrated dispensing (MID), how it is implemented in oncology care settings, and the associated advantages and ...

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Under terms announced in December, Cencora acquired shares in OneOncology from TPG and other shareholders for approximately ...

The rationale behind the treatment is that, because genetic FXI deficiency has been linked with reduced risk of ischemic ...

Alteplase, a “clot-buster” medication used to treat ischemic stroke, acute myocardial infarctions, and acute pulmonary ...

In combined analysis (n = 39), the average wound closure rate was 98%, and all 19 patients previously diagnosed for potential ...

Elevating CMS oversight operationalizes Any Willing Provider by mandating “reasonable and relevant” participation terms, ...

Kenneth Komorny, PharmD, BCPS, is vice president and chief pharmacy officer at Moffitt Cancer Center in Tampa, Florida. MID ...

First announced in September 2025, the online platform is set to offer access to prescription medications at steep discounts, ...